Home > Oncology > ASCO 2019 > Head and Neck Cancer > Ado-trastuzumab Emtansine a Potential New Treatment Option for HER2-amplified Advanced Salivary Gland Cancer

Ado-trastuzumab Emtansine a Potential New Treatment Option for HER2-amplified Advanced Salivary Gland Cancer

Presented By
Dr Bob T. Li, Memorial Sloan Kettering Cancer Centre, USA
Conference
ASCO 2019

Medical writer: Kara Nyberg, PhD

Ado-trastuzumab emtansine, the antibody-drug conjugate more commonly known as T-DM1, demonstrated robust activity in HER2-amplified salivary gland cancer (SGC) within a phase II basket trial, warranting further investigation in this disease (Abstract 6001). Among the 10 patients with SGC treated with T-DM1, nine obtained an objective response, six of which were complete responses.

The median duration of response and median progression-free survival have yet to be reached despite a median follow-up of 12 months (range: 4 to 20 months).

To gain ground in this rare malignancy, researchers are capitalizing on the targetable mutations offered up by the diverse molecular landscape of SGC. HER2 gene amplification identified through next-generation sequencing (NGS) occurs in 8% of patients with SGC and approximately 30% of patients with the aggressive salivary duct carcinoma histologic subtype.1 B...



please login to read the entire article:


You need to register to read the entire article, please do so now.





Posted on